Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors
Graphical abstract
Section snippets
Acknowledgements
We are grateful for the support of the NIH (DK 46335), the Skaggs Institute for Chemical Biology and the Lita Annenberg Hazen Foundation (JWK), as well as startup funding from the Indiana University School of Medicine, Department of Biochemistry and Molecular Biology (SMJ). David Mortenson is supported by a postdoctoral fellowship from the Hewitt Foundation. While tafamidis was discovered at The Scripps Research Institute, it was developed at FoldRx Pharmaceuticals by the substantial expertise
References (68)
- et al.
Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology
Lab Invest
(2003) - et al.
The biological and chemical basis for tissue selective amyloid disease
Cell
(2005) - et al.
The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug
J Mol Biol
(2012) Alternative conformations of amyloidogenic proteins govern their behavior
Curr Opin Struct Biol
(1996)- et al.
Kinetic stabilization of the native state by protein engineering: Implications for inhibition of transthyretin amyloidogenesis
J Mol Biol
(2005) - et al.
Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors
Bioorg Med Chem Lett
(1999) - et al.
Discovering transthyretin amyloid fibril inhibitors by limited screening
Bioorg Med Chem
(1998) - et al.
Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid
Bioorg Med Chem
(1999) - et al.
Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants
Lab Invest
(2004) - et al.
Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity
Chem Biol
(2004)
Design, synthesis, and evaluation of oxazole transthyretin amyloidogenesis inhibitors
Bioorg Med Chem Lett
(2005)
Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses
Curr Opin Struct Biol
(2010)
Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis
Neurosci Res
(2006)
The systemic amyloidoses
Curr Opin Rheumatol
(2004)
The genetics of the amyloidoses
Annu Rev Med
(2000)
Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans
N Engl J Med
(1997)
The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis
Proc Natl Acad Sci USA
(2001)
Human brain amyloidoses
Nephrol Dial Transplant
(1998)
Fibril in senile systemic amyloidosis is derived from normal transthyretin
Proc Natl Acad Sci USA
(1990)
Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity
Neurology
(2002)
Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (north of Portugal)
Am J Med Genet
(1995)
Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease
Biochemistry
(1995)
D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?
Biochemistry
(2003)
Amyloidosis
Crit Rev Clin Lab Sci
(1994)
Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations
Amyloid
(2003)
Understanding and ameliorating the transthyretin amyloidoses
Protein folding and misfolding
Nature
(2003)
Folding proteins in fatal ways
Nature
(2003)
Transthyretin cardiac amyloidoses in older North Americans
J Am Geriatr Soc
(2012)
Ocular manifestations in liver transplant recipients with familial amyloid polyneuropathy
Acta Ophthalmol
(2008)
Manifestations of transthyretin-related familial amyloidotic polyneuropathy: long-term follow-up of Japanese patients after liver transplantation
Surg Today
(2011)
Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments
J Neurol Neurosurg Psychiatry
(2015)
Guideline of transthyretin-related hereditary amyloidosis for clinicians
Orphanet J Rare Dis
(2013)
Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis
Neurology
(2016)
Cited by (0)
© 2017 Elsevier Ltd. All rights reserved.